ESMO 2022 | Metastatic breast cancer at ESMO 2022: TROPiCS02, MONARCH 3 and SYNERGY

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of the latest updates in metastatic breast cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France. Firstly, Dr Agostinetto discusses the TROPiCS-02 trial (NCT03901339) which evaluated sacituzumab govetican in patients with HR+/HER2-negative breast cancer. Sacituzumab govetican significantly improves overall survival vs single agent chemotherapy of physicians choice in pretreated advanced HR+/HER2- advanced breast cancer. Secondly, Dr Agostinetto highlights the results from the MONARCH 3 trial (NCT02246621) where the interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer demonstrate a longer overall survival however did not meet the threshold for formal statistical significance. The final study discussed by Dr Agostinetto is the SYNERGY trial (NCT03616886) which investigated the role of oleclumab, an anti-CD73 monoclonal antibody, in combination with durvalumab and chemotherapy in patients with metastatic triple negative breast cancer (mTNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.